233276-27-2

Upstream product

• 262422-89-9 benzoic acid N'-(6-chloro-5-trimethylsilanyl-pyridazin-3-yl)-hydrazide 
• 130825-12-6 3,6-dichloro-4-(trimethylsilyl)pyridazine 
• 262422-90-2 6-chloro-3-phenyl-7-trimethylsilanyl-[1,2,4]triazolo[4,3-b]pyridazine 
• 233276-24-9 3-chloro-6-hydrazinyl-4-(trimethylsilyl)pyridazine 

Downstream Products

• 233276-28-3 6-chloro-3-(2-fluorophenyl)-7-(1-hydroxycyclobutyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 1261174-82-6 2-(6-chloro-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)-propan-1,1,1,3,3,3-d6-2-ol 
• 1261174-58-6 2-(6-((1-ethyl-1H-1,2,4-triazol-5-yl)methoxy)-3-(2-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-7-yl)propan-1,1,1,3,3,3-d6-2-ol 
• 233276-30-7 7-bromo-6-chloro-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine 
• 233276-31-8 7-Bromo-3-(2-fluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3-ylmethoxy)-1,2,4-triazolo [4,3-b]pyridazine 

Relevant academic research and scientific papers

DEUTERIUM-MODIFIED TRIAZOLO-PYRIDAZINE DERIVATIVES AS GABA-A RECEPTOR MODULATORS

This invention relates to deuterated substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an αl-GABAA receptor antagonist or an α2- and/or an α3-GABAA receptor partial agonist.

Rapid analogue synthesis of trisubstituted triazolo[4,3-b]pyridazines

A rapid analogue synthesis of biologically active 3,6,7-trisubstituted 1,2,4-triazolo[4,3-b]pyridazines was devised to give easy and selective variation of the three substituents through combinations of silicon-directed anion formation, palladium-catalysed couplings and S(N)Ar displacements. (C) 2000 Elsevier Science Ltd.